THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Abdulrafeh Naqash to Antibodies, Monoclonal

Back to Details
This is a "connection" page, showing publications Abdulrafeh Naqash has written about Antibodies, Monoclonal.
Abdulrafeh Naqash
Connection Strength
0.660
Antibodies, Monoclonal
  1. Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report. Acta Oncol. 2018 05; 57(5):705-708.
    View in: PubMed
    Score: 0.516
  2. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. J Clin Oncol. 2019 10 20; 37(30):2738-2745.
    View in: PubMed
    Score: 0.143
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES